IL-22 Is Mainly Produced by IFNγ-Secreting Cells but Is Dispensable for Host Protection against Mycobacterium tuberculosis Infection

Jochen Behrends¹, Jean-Christophe Renauld², Stefan Ehlers³,⁴,⁵, Christoph Hölscher¹,⁵*

¹ Infection Immunology, Research Center Borstel (RCB), Borstel, Germany, ² Ludwig Institute for Cancer Research and Experimental Medicine Unit, Université Catholique de Louvain, Brussels, Belgium, ³ Microbial Inflammation Research, RCB, Borstel, Germany, ⁴ Molecular Inflammation Medicine, Christian-Albrechts-University, Kiel, Germany, ⁵ Cluster of Excellence Inflammation-at-Interfaces (Borstel-Kiel-Lübeck-Plön), Germany

Abstract

Anti-inflammatory treatment of autoimmune diseases is associated with an increased risk of reactivation tuberculosis (TB). Besides interleukin (IL)-17A, IL-22 represents a classical T helper (TH)17 cytokine and shares similar pathological effects in inflammatory diseases such as psoriasis or arthritis. Whereas IL-17A supports protective immune responses during mycobacterial infections, the role of IL-22 after infection with Mycobacterium tuberculosis (Mtb) is yet poorly characterized. Therefore, we here characterize the cell types producing IL-22 and the protective function of this cytokine during experimental TB in mice. Like IL-17A, IL-22 is expressed early after infection with Mtb in an IL-23-dependent manner. Surprisingly, the majority of IL-22-producing cells are not positive for IL-17A but have rather functional characteristics of interferon-gamma-producing TH1 cells. Although we found minor differences in the number of naive and central memory T cells as well as in the frequency of TH1 and polyfunctional T cells in mice deficient for IL-22, the absence of IL-22 does not affect the outcome of Mtb infection. Our study revealed that although produced by TH1 cells, IL-22 is dispensable for protective immune responses during TB. Therefore, targeting of IL-22 in inflammatory disease may represent a therapeutic approach that does not incur the danger of reactivation TB.

Introduction

Reactivation of latent tuberculosis (TB) after therapeutic tumor necrosis factor (TNF) blockade during chronic inflammatory diseases such as rheumatoid arthritis highlights TNF as an essential mediator containment of infection with Mycobacterium tuberculosis (Mtb) [1–4]. Therefore, current inflammation research aims at discovering new targets that selectively block disease-promoting mechanisms during inflammatory diseases without compromising protective immune responses against Mtb.

Innate immune cells alone are not capable to control Mtb infection [5] but the induction of an acquired immune response is essential for a protective host immune defense of Mtb [6,7]. Particularly the interleukin (IL)-12-mediated differentiation of T helper (TH)1 cells promote the production of interferon-gamma (IFNγ) and TNF, which in turn are essential to activate effector mechanisms in macrophages for controlling the intracellular growth of Mtb [8–10]. In addition, these cytokines also play an important role in the formation of granulomas, a well-structured accumulation of immune cells required for the containment of mycobacterial replication [11–13], that may also contribute to immunopathology and bacterial dissemination [14–16].

In contrast to IFNγ- and TNF-secreting TH1 cells, TH17 cells are defined by their production of IL-17A, IL-17F, IL-21, and IL-22 [17,18]. After infection with Mtb, the proliferation of IL-17A-producing cells is dependent on IL-23, which mediates protective mechanisms in the absence of IL-12 [19–22]. IL-17A contributes to the host’s immune defense by the induction of chemokines and cytokines that are responsible for the early recruitment of neutrophils and granuloma formation [23,24]. Furthermore, IL-17A is involved in the establishment of protective TH1 cell responses after vaccination against Mtb [25,26]. In contrast to this protective function, overproduction of IL-17A may also have pathological effects during Mtb-induced inflammation [27]. After Mtb infection, IL-17A is mainly produced by γδT cells rather than CD4+ T cells [28]. The differential role of these two T cell populations still remains elusive [29].

The imponderability of different cytokines towards protection or pathology during inflammation is even greater if another TH17 cytokine, IL-22 is considered. IL-22 is a member of the IL-10 family, mainly produced by T cells and natural killer (NK) cells and represents an effector cytokine of the TH17 lineage [30–33] that mediates immunopathology in inflammatory diseases, such as psoriasis or arthritis [34–36]. IL-22 acts through a receptor complex consisting of the private IL-22 receptor type I and the IL-10 receptor (R)2 subunits that is expressed on various cell types such as keratinocytes and fibroblasts. It induces pro-inflammatory chemokines and cytokines, antimicrobial peptides and proteins involved in tissue remodeling [33,37–40]. However, IL-22 shares...
some downstream effects with IL-10 [38,41] and can act immunosuppressive during airway inflammation through an IL-10 associated mechanism [42]. Overall, targeting IL-22 or its receptors represents a promising approach to ameliorate the outcome of autoimmune diseases such as psoriasis or psoriatic [43,44]. However, the treatment of such diseases with anti-inflammatory drugs has been associated with reactivation of latent TB [45,46]. To evaluate the potential risk of interfering with IL-22-dependent inflammation on the outcome of Mtb infection, we analyzed IL-22-deficient (−/−) mice in experimental pulmonary TB, because the impact of IL-22 on protective immune responses during mycobacterial infections is currently poorly understood. In human macrophages NK cell-derived IL-22 inhibits the intracellular growth of Mtb [47,48]. In a murine aerosol model, IL-22 has been shown to contribute to chemokine (G-X-C motif) ligand (CXCL)13-mediated B cell follicle organization in granulomas, which appears to have a protective function during Mtb infection [48–52]. However, neutralization of IL-22 has no influence on the outcome of experimental TB [53]. Together, after infection with Mtb the cellular sources of this TH17 cytokine are not defined and the impact of IL-22 on protective immune responses is not clearly understood yet. To evaluate whether therapeutic targeting of IL-22 represents a promising approach for the therapy of autoimmune diseases without compromising cell-mediated immunity in Mtb infection, we here determined the IL-22-producing cell types and determined the functional and protective significance of IL-22 using IL-22−/− mice in an experimental aerosol model of TB.

Materials and Methods

Mice

IL-22−/− mice were bred and maintained under specific-pathogen-free conditions at the Research Center Borstel. IL-22p19−/− mice were obtained from the Institute of Animal Breeding and Husbandry at the Christian-Albrechts-University (Kiel, Germany) and C57BL/6 mice (Charles River, Sulzdorf, Germany) were used as controls. Experimental mice were between 8 and 16 weeks old. In any given experiment, mice were matched for age, sex and genetic background. For infection experiments, mice were kept under barrier conditions in the BSL 3 facility at the Research Center Borstel (Borstel, Germany) in individually ventilated cages. All experiments performed were in accordance with the German Animal Protection Law and were approved by the Animal Research Ethics Board of the Ministry of Environment, Kiel, Germany.

Bacteria and Infection

For infection experiments, Mtb H37Rv were used. Mtb was grown in Middlebrook 7H9 broth (Difco, Detroit, MI) supplemented with Middlebrook OADC enrichment medium (Life Technologies, Gaithersburg, MI), 0.002% glycerol, and 0.05% Tween 80. Midlog phase cultures were harvested, aliquoted, and frozen at -80°C. Before infection of experimental animals, stock solutions of Mtb were diluted in sterile distilled water and pulmonary infection was performed using an experimental aerosol inhalation exposure system (Glas-Col, Terre-Haute, IN). To infect mice with a low dose (100–200 CFU/house) or high dose (1000–2000 CFU/house), animals were exposed for 40 min to an aerosol generated by nebulising approximately 5.5 ml of a suspension containing 10⁷–10⁸ live bacteria. Inoculum size was checked 24 h after infection by determining the bacterial load in the lung of infected mice.

Colony Enumeration Assay

Bacterial loads in lungs, spleen and liver were evaluated at different time points after infection with Mtb to follow the course of infection. Organs from sacrificed animals were removed aseptically, weighed and homogenized in PBS containing a proteinase inhibitor cocktail (Roche Diagnostics, Mannheim, Germany) prepared according to the manufacturer’s instructions. Tenfold serial dilutions of organ homogenates were plated in duplicates onto Middlebrook 7H10 agar plates containing 10% OADC and incubated at 37°C for 21–25 days. Colonies on plates were enumerated and results expressed as log₁₀ CFU per organ.

Preparation of Single Cell Suspensions from Infected Lungs

For antigen-specific restimulation and flow cytometric analysis, single cell suspensions of lungs were prepared from Mtb-infected mice at different time points. Mice were anesthetized and injected intraperitoneally with 150 U Heparin (Ratiopharm, Ulm, Germany). Lungs were perfused through the right ventricle with warm PBS. Once lungs appeared white, they were removed and sectioned. Dissected lung tissue was then incubated in collagenase A (0.7 mg/ml; Roche Diagnostics, Mannheim, Germany) and DNase (10 μg/ml; Sigma) at 37°C for 2 h. Digested lung tissue was gently disrupted by subsequent passage through a 100 μm pore size nylon cell strainer. Recovered vital lung cells were counted using an automatic cell counter (ViCell®, Beckman Coulter, Krefeld, Germany), diluted in complete Iscove’s-modified Dulbecco’s medium (IMDM; Gibco) supplemented with 10% FCS (Gibco), 0.05 mM β-mercaptoethanol (Sigma, Deisenhofen, Germany), and penicillin and streptomycin (100 U/ml and 100 μg/ml; Gibco) and used for further experiments.

Flow Cytometric Analysis

For flow cytometric analysis of surface markers and intracellular cytokines, enriched CD4+ T cells, and single-cell suspensions of lungs were stained with optimal concentrations of the following specific antibodies against surface molecules and intracellular cytokines: CD8 α-V450, CD4-V500, CD11c-FITC, CD62L-APC, Gr-1-APC, IFNγ-APC from BD Biosciences, CD11b-PerCP-Cy5.5, IL-17A-PerCP-Cy5.5, CD90.2-PE-Cy7, CD90.2-APC from BD Biosciences, IL-22-PE-Cy7, IL-4-PE-Cy7, IL-10-PE-Cy7, and HMC1-1A-1-E-PEFluor780 from eBioscience, CD44-FTTC, and IFNγ-PE from BioLegend, and IL-22-PE from R&D Systems. Fluorescence intensity was measured by using a FacsCantoII® flow cytometer (BD Bioscience) equipped with a 405 nm, 488 nm and 633 nm laser. Analysis was performed utilizing the FCSExpress® program (DeNovo™ Software) gated on leukocytes identified by the forward-scatter/side-scatter profile and further characterization as specified in the figures.

RT-PCR

Weighed lung samples before and at different time points after aerosol infection with Mtb, were homogenized in 4 M guanidinium-isothiocyanate buffer and total RNA was extracted by acid phenol extraction. cDNA was obtained using murine moloney leukemia virus (MMLV) reverse transcriptase (Superscript II, Invitrogen, Karlsruhe, Germany) and oligo-dT (12–18mer; Sigma) as a primer. Quantitative PCR was performed on a Light Cycler (Roche Diagnostics Corporation, Indianapolis, IN). Data were analyzed employing the “Fit Points” and “Standard Curve Method” using hypoxanthine-guanine phosphoribosyltransferase (Hprt) as housekeeping gene to calculate the level of gene expression in relation to Hprt. The following primer and probe sets were employed:
**Hprt**: sense 5'-TCC TCA GAC CGC TTT T-3', antisense 5'-CCT GGT TCA TCA TCG CTA ATC-3', probe 5'-AGT CCA G-3'.

**Il-22**: sense 5'-TTT CCT GAC CAA ACT CAG CA-3', antisense 5'-TCT GGA TGT TCT GGT CGT CA-3', probe 5'-CAG CTC CT-3'.

**Il-12b**: sense 5'-ATC GTT TTG CTG GTG TCT CC-3', antisense 5'-GGA GTC CAG TCC ACC TCT ACA-3', probe 5'-AGC TGG AG-3'.

**Il-17a**: sense 5'-TGT GAA GGT CAA CCT CAG AGT CT-3', antisense 5'-GAG GGA TAT CTA TCA GGG TCT T-3', probe 5'-CTG CCA GCC CCT CAA TCA-3', antisense 5'-AAC GGC ACT AAC ATG TGA CAA TCA-3', probe 5'-ATG GCT GC-3'.

**Tnf**: sense 5'-TCT TCT CAT TCC TGC TTG TGG-3', antisense 5'-GGT CTG GGC CAT AGA ACT GA-3', probe 5'-TGG TGG CC-3'.

**Il-10**: sense 5'-CAG AGC CAC ATG CTA CTA GA-3', antisense 5'-GTC CAG CTG TGC CTT TGT TT-3', probe 5'-CTG CAG CC-3'.

**Il-23p19**: sense 5'-TTT TGG CAT TCC AAC GAG AGG AAA TTA-3', antisense 5'-TTC AGG ACT TCA AAG AGT CTG AGG TA-3', probe 5'-CAG AGC CA-3'.

**Nos2**: sense 5'-CTT TGC CAC GGA CGA GAC-3', antisense 5'-GTC ATT GTA CTC TGA CTA CAA-3', probe 5'-AGG CAG AG-3'.

**Lrg47**: sense 5'-AAG GCC ACT AAC ATC GAA TCA-3', antisense 5'-ATG GAC AGA AAG ACA TAG TTA GAA GAA-3', antisense 5'-GAA CAG TAG CAA AGA CTT GAC CA-3', probe 5'-ATG GCT GC-3'.

**Ifng**: sense 5'-ATC TTG AGG AAC TGG CAA AAT-3', antisense 5'-AGC TGG AG-3'.

**Il-17f**: sense 5'-CCG AGG AAG ACA TAG TTA GAA GAA A-3', antisense 5'-CAG TAG CAA AGA CTT GAC CA-3', probe 5'-ATG GCT GC-3'.

**Light-Cycler DNA Master SYBR Green**

PCR was performed using the proprietary Light-Cycler-DNA Master SYBR Green® I kit (Roche Diagnostics) and the following primer sets:

**Hprt**: sense 5'-TCC TCA GAC CGC TTT T-3', antisense 5'-CCT GGT TCA TCA TCG CTA ATC-3', probe 5'-AGT CCA G-3'.

**Il-23p19**: sense 5'-TTT TGG CAT TCC AAC GAG AGG AAA TTA-3', antisense 5'-TTC AGG ACT TCA AAG AGT CTG AGG TA-3', probe 5'-CAG AGC CA-3'.

After amplification, melting curve analysis was performed to exclude the presence of confounding primer-dimers during quantification. For purposes of statistical comparison, units were normalized by calculating the cDNA ratios of gene-of-interest/Hprt for each sample.

**Intracellular Cytokine Staining**

For detection of intracellular IFNγ, IL-22 and IL17A an intracellular cytokine staining kit was employed (BD Biosciences).
Figure 2. In experimental TB, IL-22 is mainly expressed by IFN-γ-producing cells. Experimental mice were infected with approx. 100 CFU Mtb via the aerosol route. (A, B). After 22 days of infection, lung cells of C57BL/6 mice were restimulated with anti-CD3/CD28 or left unstimulated. Cells were subsequently stained for CD90.2, CD4, IL-17A, IFN-γ and IL-22, analyzed by flow cytometry and the frequencies of cytokine-producing cells were compared. (A) Representative dot plots and frequencies of cytokine-producing CD4<sup>−</sup> (left panel, left graph) and CD4<sup>+</sup> (right panel, right graph) cells gated for CD90.2<sup>+</sup>. The frequencies of gated cytokine-producing cells are shown and represent means ± SD of 5 mice. (B) Representative dot plots of control stainings (i, isotype controls; ii, unstimulated cells; iii, staining in IL-22<sup>−/−</sup> mice) and of cytokine-producing cells indicating G1 (IFN-γ<sup>+</sup>/IL-22<sup>−</sup>), G2 (IFN-γ<sup>+</sup>/IL-22<sup>−</sup>) and G3 (IFN-γ<sup>+</sup>/IL-22<sup>−</sup>) for further analysis. The absolute numbers and frequencies of gated cytokine-producing cells are shown and represent means ± SD of 5 mice. Statistical analysis was performed using two-way ANOVA defining differences between different cytokine-producing cell populations as significant (***, p<0.001).

doi:10.1371/journal.pone.0057379.g002
Briefly, single cell suspensions were prepared at 22–254 days after infection and 1.8×10⁶ cells were incubated without or with plate-bound anti-CD3/CD28 mAb (clone 2C11 and clone 37/51 at 5 μg/ml, respectively) for 4.5 h in the presence of GolgiPlug™ (BD Biosciences). Non-specific antibody binding was blocked by incubation with a cocktail containing anti-FcγRIII/II mAb (clone 2.4G2), mouse, hamster and rat serum. Cells were washed and incubated with optimal concentrations of V450, V500, FITC and PE-Cy7 labelled mAbs directed against CD8α, CD44 (BioLegend), and CD90.2 (eBioscience). After staining, cells were fixed and permeabilized with Cytotox/Cytoperm™ (BD Biosciences) and intracellularly accumulated IL-22, IL-17A, and IFNγ were stained with PE (R&D Systems), PerCP-Cy5.5 (eBioscience), and APC (BD Biosciences) labelled mAbs. IgG2a-PE, IgG2a-PerCP-Cy5.5 and IgG1-APC antibodies were applied for isotype control stainings. Fluorescence intensity was analysed on a FacsCantoII® (BD Biosciences) gated as described in the figures.

ESAT6_1–20-specific ELISPOT Assays

For measuring antigen-specific CD4⁺ T cells in lungs from infected mice, single cell suspension were resuspended in IMDM. To enrich CD4⁺ T cells, single cell suspensions were incubated with magnetic CD4 microbeads (Miltenyi, Bergisch Gladbach, Germany) and separated from other cells on a MACS separation unit (Miltenyi). Separated CD4⁺ T cells were collected in IMDM, counted using a cell counter (ViCell®, Beckman Coulter), diluted in IMDM and used for further experiments. Purity of enriched CD4⁺ T cells was >90% as determined by flow cytometry. Detection of antigen-specific IFNγ- and IL-17-A producing CD4⁺ T cells from infected lungs was conducted using ELISPOT assay kits (BD Bioscience and R&D Systems, Wiesbaden-Nordenstadt, Germany, respectively). In brief, purified CD4⁺ T cells or single cell suspensions from lungs of infected mice were seeded in wells of anti-mouse IFNγ- or IL-17-A coated and blocked 96-well multi test plates at an initial concentration of 1×10⁵ cells/well in IMDM. After doubling dilutions of these cells were made, mitomycin-D (Sigma)-inactivated splenocytes from uninfected wild-type mice were used as APCs at a concentration of 1×10⁶ cells/well. CD4⁺ T cells and single cell suspensions were restimulated with the Mtb ESAT6_1–20 (Research Center Borstel, Germany) at a concentration of 10 μg/ml in the presence of 10 U/ml recombinant mouse IL-2 (Peprotech). After 20 h of incubation in 5% CO₂ at 37°C, plates were washed, and biotinylated anti-mouse IFNγ was used to detect the captured cytokine. Spots were visualized using streptavidin-HRP as substrate. After 24 h of incubation in 5% CO₂ at 37°C, plates were washed, and biotinylated anti-mouse IL-17A was used to detect the captured cytokine. Spots were visualized using streptavidin-AP as substrate. Spots were automatically enumerated using an ELISPOT reader (EliSpot 04 XI; AID). The frequency of responding CD4⁺ T cells or responding cells from each cell suspension was determined. Neither CD4⁺ T cells or single cell suspension cells cultured in the absence of ESAT6_1–20 nor cells from uninfected mice produced detectable spots.

Statistical Analysis

Quantifiable data are expressed as means of individual determinations and standard errors. Statistical analysis was used with the Prism software program (GraphPad Software) to perform two-tailed Student t test or two-way ANOVA and Bonferroni’s multiple comparison post-test as appropriate. Differences were considered significant when p<0.05. The log-rank (Mantel-Cox) test was used for statistical analysis for survival experiments.

Results

After Mtb Infection, IL-22 Expression is Dependent on IL-23

Early after infection of C57BL/6 mice with Mtb real time RT-PCR of lung homogenates was conducted to compare gene expression of Il22 with the expression of Il17a, Il17f, Il12b, and Il23p19 (Figure 1A). Uninfected mice expressed very low mRNA levels of these cytokines. Gene expression of Il22, Il17a, Il17f, and Il12b started to increase as early as day 14 of Mtb infection. Maximal expression of Il22, Il17a, and Il17f were found at day 21 after which mRNA levels decreased to negligible amounts at day 35. In contrast, Il12b gene expression increased starting at day 14 with a plateau 28 days after Mtb infection. Gene expression of Il23p19 was not induced after an infection with Mtb. IL-22 has been shown to be co-expressed in TH17 cells with IL-17A [32]. To directly assess the question which cell types produce IL-17A, IFNγ, and IL-22 during experimental TB, C57BL/6 mice were infected with 1.8×10⁵ CFU Mtb via the aerosol route. At (A) and (B) later time points, gene expression of Il2b, Tnf, Il6, and Il10 was quantified by real time RT-PCR in lung homogenates of C57BL/6 mice based on the expression of Hprt. Data represent mean ± SD of 5 mice per group. Statistical analysis was performed using a two-way ANOVA defining differences between C57BL/6 and IL-22⁻/⁻ mice as significant (*, p<0.05).

During Experimental TB, IL-22 is Mainly Expressed by IFNγ-producing Cells

It is assumed that IL-22 is co-expressed in TH17 cells with IL-17A [32]. To directly assess the question which cell types produce IL-22 during experimental TB, C57BL/6 mice were infected with a low dose of Mtb for 22 days, and the production of IL-17A, IFNγ and IL-22 in CD90.2⁺CD4⁺T cells was analysed by flow cytometry after restimulation of lung cells with anti-CD3/CD28 and intracellular cytokine staining (Figure 2). The analysis encompasses four distinct CD90.2⁺ cytokine-producing populations (Figure 2A): IL-17A⁺ or IL-22⁺ cells negative for CD4, and CD4⁺ cells, which were capable to produce IL-17A⁺ or IL-22⁺. The frequency of IL-17A producing cells was enhanced in the CD90.2⁺CD4⁺ population (8.1%) when compared to CD90.2⁺CD4⁻ cells (5.4%), but the relative amount of IL-22-producing cells was higher in the CD90.2⁺CD4⁺ population (5.8%) compared to CD90.2⁺CD4⁻ cells (4.2%). Interestingly, after restimulation, the frequency of IL-17A-producing cells was approx. 10-fold higher in CD90.2⁺CD4⁻ cells compared to an only 5-fold increased relative amount of IL-17A⁺CD90.2⁺CD4⁻ cells. Moreover, the frequency of IL-22⁺CD90.2⁺CD4⁻ cells increased to a higher extent (approx. 5-fold) when compared to IL-22⁺CD90.2⁺CD4⁺.
IL-22 represents mean ± SD of 4-5 mice per group. Statistical analysis was performed using a two-way ANOVA defining differences between C57BL/6 and IL-22-/- mice as significant (*, p<0.05; **, p<0.01; ***, p<0.001).

doi:10.1371/journal.pone.0057379.g004

cells (approx. 3-fold). CD90.2+CD4+ cells that only produce IL-22 were hardly detectable in lungs of Mtb-infected mice (0.6%). Surprisingly, most IL-22-producing cells were found not to be positive for IL-17A (approx. 90%).

Therefore, we further characterised cells producing IL-22 during experimental TB and surprisingly found that the majority of IL-22+CD90.2+ cells simultaneously expressed IFNγ (Figure 2B). IFNγ+IL-22+/CD4+ (G1) cells were inducible upon stimulation (approx. 14-fold) and consisted of 67% CD4+ and 27% CD8+ cells. IFNγ+IL-22+ (G2) cells showed a very low intracellular accumulation of cytokines when left unstimulated and cytokine expression was strongly enhanced after restimulation (approx. 59-fold). CD4+ cells represent 45% of this population and 38% were found positive for CD8. In contrast to these IFNγ-expressing populations, IFNγ+IL-22+/CD4+ (G3) cells could hardly be restimulated with anti-CD3/CD28 (approx. 1.4-fold) and consisted of 53% CD4+ and 13% CD8+ cells. Together, we found that during experimental TB IL-22 is mainly produced by IFNγ-expressing CD4+ T cells.

The Inflammatory Cytokine Responses in IL-22−/− Mice after Low Dose Mtb Infection

IL-22 has been shown to mediate immunopathology in inflammatory diseases and to promote innate immune responses during intra- and extracellular bacterial or fungal infections [32,34,35,54–57]. To evaluate the impact of IL-22 on the inflammatory immune response, the relative mRNA expression of pro- and anti-inflammatory cytokines (Il12b, Tnf, Il6, Il10) was quantified in lung homogenates of C57BL/6 and IL-22−/− mice at earlier (Fig. 3A) and later (Fig. 3B) time points of low dose Mtb infection. Whereas expression of the IL-22-dependent genes Il12b and Cxcl10 [56,57] was slightly reduced in IL-22−/− mice (data not shown), gene expression of Il12b, Tnf and Il10 was comparable in C57BL/6 and IL-22−/− mice. Only the expression of Il6 was slightly enhanced in IL-22−/− mice at day 42. These results indicate that, after low dose infection with Mtb IL-22 is not required for the efficient induction of an inflammatory immune response.

The Recruitment of Macrophages, Granulocytes, and Activation of T cells in IL-22−/− Mice after Low Dose Mtb Infection

Effective recruitment of different leukocyte populations such as macrophages and lymphocytes in the lungs of infected mice is essential for the generation of a protective immune defence against Mtb. Therefore, we assessed the infiltration of these different cell populations into the lungs of C57BL/6 and IL-22−/− mice at early and late time points of low dose Mtb infection (Figure 4). The total number of cells recruited to the lungs of IL-22−/− mice was not significantly different to those found in the lungs of C57BL/6 mice (Figure 4A). During the course of Mtb infection, the amounts of macrophages (CD11b+CD11c+MHCII+Gr-1+), granulocytes (CD11b+CD11c+Gr-1+), and T cells (CD4+ and CD8+) were also compared in both mouse strains (Figure 4A). Central and effector memory T cells play an important role to sustain adaptive immune responses during long term Mtb infection [58,59]. To examine the development of memory T cells we defined three different CD4+ and CD8+ T cell subsets by flow cytometry (Figure 4B): naive T cells (CD62L+CD44neg), effector memory T cells (CD62LnegCD44+), and central memory T cells (CD62LnegCD44+). For both, C57BL/6 and IL-22−/− mice, we saw similar results (Figure 4C) during the course of Mtb infection at days 22, 43, 113, 219, and 254. Compared to C57BL/6 mice, the numbers of naive as well as of effector memory T cells were slightly decreased in the lungs of IL-22−/− mice, whereas the amounts of central memory T cells increased at later time points. However, significant differences between C57BL/6 and IL-22−/− mice were only seen at d43 and d219 of infection with reduced numbers of naive CD4+ T cells and increased amounts of central memory T cells in mutant mice, respectively.

The Development of TH1 and TH17 Immune Responses in Mtb-infected IL-22−/− Mice

A TH1 immune response is central to macrophage activation and the subsequent elimination of intracellular mycobacteria by the production of IFNγ. However, IL-17A-secreting TH17 cells have also implicated in promoting protective effector mechanisms [25,28]. To determine the capability of CD4+ and CD8+ cells to produce IFNγ or IL-17A in the absence of IL-22, we performed intracellular cytokine staining and flow cytometric analysis of lymphocytes isolated from lungs of C57BL/6 and IL-22−/− mice at different time points of low dose Mtb infection. Lung cells were incubated with medium alone or were restimulated with plate bound anti-CD3/CD28. Unstimulated suspensions did not contain appreciable frequencies of IFNγ- or IL-17A-producing CD4+ or CD8+ cells, but upon stimulation three cytokine-producing CD4+ and CD8+ populations were detectable (Fig. 5A): IFNγ+IL-17A+, IFNγIL-17A−, and IFNγIL-17A−. In general, no differences between C57BL/6 and IL-22−/− mice in the frequencies of these cell populations were detected (Figure 5B). At some time points slightly different frequencies of CD4+IFNγIL-17A−, CD4+IFNγIL-17A−, CD8+IFNγIL-17A−, and CD4+IFNγIL-17A− cells were found (Figure 5B). However, these differences between C57BL/6 and IL-22−/− mice were not consistent during the course of low dose Mtb infection.

We next evaluated antigen-specific TH1 and TH17 immune responses in C57BL/6 and IL-22−/− mice at early (Figure 6A–D, left panel) and late (Figure 6A-D, right panel) time points of low dose Mtb infection. The frequency of ESAT6_18–27-specific IFNγ- and IL-17A-producing TH1 and TH17 cells, respectively, were determined within an enriched CD4+ cell population (Figure 6A, C) and within total cell suspensions (Figure 6B, D) isolated from lungs of infected mice by ELISPOT assays. During the course of low dose infection, both, C57BL/6 and IL-22−/− mice generated similar frequencies of Mtb-specific TH1 and TH17 cells within the CD4+ cell population and within total lung cell suspensions. However, at day 254 of infection, Mtb-specific IL-17A-producing CD4+ T cells were significantly enhanced in IL-22−/− mice.
Figure 5. TH1 and TH17 immune responses in IL-22⁻/⁻ mice after low dose infection with Mtb. C57BL/6 mice (black bars) and IL-22⁻/⁻ (white bars) mice were infected with approx. 100 CFU Mtb via the aerosol route. At different time points, single cell suspensions of lungs were prepared, restimulated with anti-CD3/CD28 and stained for flow cytometric analysis. (A) Representative dot plots of restimulated cells from C57BL/6 mice stained with isotype control antibodies. (B) Representative dot plots of unstimulated (left panel) or restimulated (right panel) IFNγ- and IL-17A-producing CD44⁺CD4⁺ and CD44⁺CD8⁺ cells isolated at day 22 after infection. (C) Frequencies of IFNγ⁻IL-17A⁺, IFNγ⁻IL-17A⁻, and IFNγ⁺IL-17A⁺CD4/CD8⁺ cells. Data represent mean ± SD of 4–5 mice per group. Statistical analysis was performed using a two-way ANOVA defining differences between C57BL/6 and IL-22⁻/⁻ mice as significant (*, p < 0.05; ***, p < 0.001).

doi:10.1371/journal.pone.0057379.g005
Figure 6. Antigen-specific production of IFNγ and IL-17A by CD4+ T cells of low dose-infected IL-22−/− mice. C57BL/6 mice (black bars) and IL-22−/− (white bars) mice were infected with approx. 100 CFU Mtb via the aerosol route. At earlier (left panel) and later (right panel) time points, the frequency of Esat-61–20 specific (A, B) IFNγ- and (C, D) IL-17A-producing cells in (A, C) cell suspensions enriched for CD4+ T cells or in (B, D) whole cell suspensions from lungs was determined by ELISPOT assay. Data represent mean ± SD of 4–5 mice per group. Statistical analysis was performed using a two-way ANOVA defining differences between C57BL/6 and IL-22−/− mice as significant (*, p<0.05). doi:10.1371/journal.pone.0057379.g006
Together, these results reveal that IL-22 has no influence on the expression of TH1 and TH17 immune responses of a low dose Mtb infection.

Macrophage Activation in Mtb-infected IL-22^{-/-} Mice

So far we have shown that after low dose infection with Mtb IL-22 is not essential for the efficient generation of inflammatory immune responses and the subsequent induction of antigen-
Figure 8. The course of low dose Mtb infection in IL-22−/− mice. C57BL/6 mice (black symbols) and IL-22−/− (white symbols) mice were infected with approx. 100 CFU Mtb via the aerosol route. At (A) earlier and (B) later time points, mycobacterial colony enumeration assays were performed in lungs, spleen, and liver. Data represent mean ± SD of 4–5 mice per group. Statistical analysis was performed using two-way ANOVA defining differences between C57BL/6 and IL-22−/− mice as significant (*, p<0.05; **, p<0.01; ***, p<0.001). (C) Survival of 10–13 infected mice per group. Statistical analysis was performed using the log-rank test.

doi:10.1371/journal.pone.0057379.g008
specific TH1 and TH17 cells. However, IL-22+CD4+ T cells are capable to inhibit intracellular Mtb replication in monocyte-derived macrophages from macaques [60]. In mice, the IFNγ-dependent expression of NOS2 and LRG-47 are absolutely required to control Mtb growth in macrophages [61,62]. Therefore, we examined the induction of these pathways in lung homogenates of C57BL/6 and IL-22−/− mice after low dose Mtb infection by real time RT-PCR. Gene expression of Ifng, Nos2 and Lrg47 were considerably induced after infection, but no differences between the expression of these genes in C57BL/6 and IL-22−/− mice were found during the course of low dose Mtb infection (Figure 7). However, gene expression of Lrg47 was slightly modulated at days 42 and 218 after Mtb infection. Overall these results indicate a less important role of IL-22 for promoting effector functions in macrophages.

The Absence of IL-22 does not Affect the Outcome of Mtb Infection

To finally evaluate whether IL-22 has any influence on the outcome of experimental TB, C57BL/6 and IL-22−/− mice were infected with low doses of Mtb via the aerosol route and the course of infection was followed (Figure 8). However, bacterial loads in the lungs of IL-22−/− mice did not significantly differ from lungs of C57BL/6 mice at early (Figure 8A) and late (Figure 8B) time points of infection. In spleens and livers of IL-22−/− mice, even slightly reduced CFU were found at some time points of Mtb infection. In line with this apparently efficient control of Mtb replication in the absence of IL-22 also no difference in survival kinetics was observed between IL-22−/− and C57BL/6 mice (Fig. 8C). These results clearly show that IL-22 is dispensable for controlling low dose Mtb infection. To evaluate whether IL-22 is required for protective immune responses after high dose Mtb infection, we infected mice with more than 1000 CFU Mtb and followed the course of infection (Figure 9A). On day 41, 71, and day 105 after infection the bacterial load in the lungs of IL-22−/− mice did not significantly differ from lungs of C57BL/6 mice, showing that IL-22−/− mice controlled bacteria as well as C57BL/6 mice up to 105 days. Earlier during infection (d21), only lungs of IL-22−/− mice could worse with Mtb infection than C57BL/6 mice showing slightly higher (~0.6 log10) bacterial

Figure 9. The course of high dose Mtb infection in IL-22−/− mice. C57BL/6 mice (black symbols) and IL-22−/− (white symbols) mice were infected with approx. 1000 CFU Mtb via the aerosol route. At (A) earlier and (B) later time points, mycobacterial colony enumeration assays were performed in lungs, spleen, and liver. Data represent mean ± SD of 5 mice per group. Statistical analysis was performed using two-way ANOVA defining differences between C57BL/6 and IL-22−/− mice as significant (**, p<0.01). (C) Survival of 10 infected mice per group. Statistical analysis was performed using the log-rank test.
doi:10.1371/journal.pone.0057379.g009
loads. No differences were found in the spleens and livers of Mtb infected C57BL/6 and IL-22−/− mice. Additionally performed flow cytometric analysis revealed no difference within the amount of T cells, macrophages, and granulocytes during the course of infection (data not shown). Furthermore, the cell-mediated immune response measured by real time RT-PCR and ELISPOT analysis was not significantly different in high dose Mtb-infected C57BL/6 and IL-22−/− mice (data not shown). In line with these findings, also no difference in survival kinetics was observed between IL-22−/− and C57BL/6 mice after high dose Mtb infection [Figure 9B]. Together, these results indicate that IL-22 is dispensable for protective immune responses during TB.

Discussion

IL-22, a member of the IL-10 family, is mainly produced by T and NK cells [33,38]. It is considered to be produced by IL-17A-secreting TH17 cells in an IL-23-dependent manner [20,32] or by a private T cell lineage termed TH22 [63,64]. In patients with inflammatory skin disorders, these TH22 cells were found to produce only IL-22 but not IFNγ, IL-4, or IL-17 [63]. We here show that after infection of C57BL/6 mice with Mtb, IL-22 expression is in fact dependent on IL-23. Most of the IL-22-expressing cells also produce IFNγ (>90%). To a minor extent T cells secret only IL-22 but co-expression by IL-17A-producing cells was hardly detectable. Hence, in contrast to current paradigm of T cell lineages defining IL-22 produced by TH17 or TH22 cells [64] IL-22 appears to be a TH1 cytokine during experimental TB. Based on in vitro studies TH17 cells have been thought for a long time to represent terminally differentiated cells but recent reports facilitated by novel tools for tracking TH17 cell fate in vivo give clear evidence of a developmental plasticity of TH17 cells [65,66]. Because the discovery of IL-17A/IFNγ co-producing cells has originally indicated a plasticity between TH17 and TH1 differentiation [17] and a recent study that analyzed TH17 cell fate during chronic inflammation in vivo demonstrated an IL-23-mediated conversion of TH17 to TH1 cells [67], IL-23-dependent IL-22-expressing TH1 cells described in the present study might represent a transition state of TH22 to TH1 cells. In Mtb infected C57BL/6 mice, most of the IFNγ/IL-22+ T cells were of the CD4 and CD8 T population but IL-22-single positive cells were mainly produced by CD4 T cells and could be considered to represent TH22 cells. A fairly prominent proportion of IL-22-single positive cells (approx. 30%) were found to be CD4+/CD8−/−CD90.2+ and may belong to the NK cell population, that has recently been described as IL-22 producing cells after Mtb infection [47]. Together, during experimental TB IL-22 is mainly produced by TH1 and TH22 cells rather than by TH17 cells and that IL-22 expression depends on IL-23. The fate of IL-22-producing cells and the potential transition into TH1 cells has to be further elucidated. Mtb infection usually results in a TH1-dominated immune response. Because TH1 cells are potent regulators of the development of IL-17A/IL-22 co-producing TH17 cells [68], the induction of TH1 cytokines may also suppress the efficient generation of TH17 cells expressing both IL-17A and IL-22 and favours the initiation of IFNγ/IL-22 co-producing cells. This bypass allows for an effective IL-22 expression without co-secretion of IL-17A.

IL-22 signals through a receptor complex, consisting of the specific IL-22 receptor type I and the IL-10R2 subunit and activates the STAT3 signaling pathways, and is capable to induce pro-inflammatory chemokines or cytokines, antimicrobial peptides, and proteins involved in tissue remodeling [32,33,37,38,64]. However, in the present study gene expression of il12b, tnf, il6, and il10 in lung of IL-22−/− mice was efficiently induced after aerosol infection with Mtb. Hence, the inflammatory cytokine response during TB is generated independently of IL-22. The effective recruitment of different leukocyte populations in the lungs of infected mice is essential for the generation of a protective immune response against Mtb [69]. We here show that during the course of Mtb infection the infiltration of macrophages, granulocytes and T cells into the lungs is facilitated independently of IL-22. Memory T cells sustain adaptive immune responses during the course of experimental TB [50]. In the present study, the differential analysis of naive, effector memory and central memory T cells also revealed that IL-22 has no general influence on the development of memory and central memory T cells after infection with Mtb. Reduced numbers of naive CD4+ T cells at early stages of infection day may be explained by slightly reduced expression of the IL-22-dependent chemokines MIP-1 and CXCL-10 in IL-22−/− mice, which are involved in activation and recruitment of T cells [56,57,70,71] (data not shown). In line with the rather unaffected development of memory and central memory T cells in Mtb-infected IL-22−/− mice the differentiation of IFNγ(IL-17A^+ T cells as well as of TH1 and TH17 cells was also fairly induced in the absence of IL-22. Irrespective of the IL-22-independent induction of inflammatory cytokines, leukocyte recruitment and T cell activation, IL-22 might activate macrophage effector mechanisms, because it has been described in different models to limit mycobacterial growth in these cells [40,60]. However, in the present study the expression of important macrophage effector molecules such as NOS2 and LRG-17 [61,62] was efficiently induced independently of IL-22. Together, our detailed analysis revealed that during experimental TB IL-22 is not essential for the generation of a cell-mediated immune response. Because IL-22 expression depends on the presence of IL-23 this phenotype very much corroborates the still efficient immune response against Mtb infection described in IL-23p19−/− mice [20].

The antimicrobial activity against several other intra- and extracellular pathogens in vivo is promoted by IL-22 [47,55,57] and also the regenerative and inflammatory effect of this cytokine is documented during influenza infection [72]. With respect to TB, IL-22 produced by CD4 T or NK cells is capable to inhibit the growth of Mtb in macrophages in vivo [48,60] indicating a protective function in vivo. However, in another context in which different infectious diseases and other cytokines were specifically evaluated IL-22−/− mice were resistant to mycobacterial infection [48,49,53]. Focusing on IL-22, our detailed analysis revealed that after infection with Mtb IL-22 has no influence on the expression of inflammatory cytokines, cellular infiltration, the expansion of memory T cells, the development of TH1 and TH17, and the expression of macrophage effector functions. Consequently, IL-22−/− mice were capable to efficiently control mycobacterial growth after low dose infection with a similar survival kinetic than infected C57BL/6 mice. Even after high dose challenge with Mtb an IL-22 deficiency has no impact on the outcome of experimental TB. Together, IL-22 alone is dispensable for host protective immune responses against Mtb and in the complex in vivo system of the here presented study IL-22 deficiency appears to be compensated by other mediators. This corroborates again the phenotype of IL-23p19−/− mice in which IL-23 deficiency is compensated by IL-12 [20]. Hence, other IL-23-dependent mediators such as IL-17A or IL-17F may therefore replace functions of IL-22. Antimicrobial peptides, associated with host defense, are cooperatively induced by IL-22, IL-17A and IL-17F, but IL-22 alone is not as strong as IL-17A or IL-17F in inducing these peptides [32]. This potential compensatory effect may
eventually aid to the efficient control of mycobacterial growth in Mtb-infected IL-22−/− mice.

Our findings that IL-22 is not essential for protective immune responses against Mtb provide evidence that IL-22-targeted therapeutics in inflammatory diseases may not incur the risk of adverse effects such as reactivation of TB.

Acknowledgments

The authors thank Johanna Voiz, Alexandra Holscher, Gabriele Roever and Kerstin Traxel for excellent technical assistance. We are also grateful to Ilka Monath, Jeanette Hein and Klaus Möller for organizing the animal facility and taking care of the mice.

Author Contributions

Conceived and designed the experiments: JB CH. Performed the experiments: JB. Analyzed the data: JB. Contributed reagents/materials/analysis tools: JCR. Wrote the paper: JB SE CH.

References

1. Alif W, Loftus EV, Jr. (2009) Safety profile of IBD therapeutics: infectious risks. Gastroenterol Clin North Am 38: 691–709.
2. Ehlers S (2005) Tumor necrosis factor and its blockade in granulomatous diseases: differential modes of action of infliximab and etanercept? Clin Infect Dis 41 Suppl 3: S199–203.
3. Solovic I, Sester M, Gomez-Reino JJ, Rieder HL, Ehlers S, et al. (2010) The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement. Eur Respir J 36: 1185–1206.
4. Stallmach A, Haggblom S, Bruns T (2010) Anti-tuberculosis effects of biologics used for treating IBD. Best Pract Res Clin Gastroenterol 24: 167–182.
5. Reiling N, Ehlers S, Holscher C (2008) MyD88 and toll-1L:ed tracter: species: interactive and effector immunity to tuberculosis. Immunol Lett 116: 15–22.
6. Cooper AM (2009) Gammadelta T cell-mediated immune responses in tuberculosis. Annu Rev Immunol 27: 393–422.
7. Orme IM, Andersen P, Boom WH (1993) T cell response to Mycobacterium bovis bacille Calmette-Guerin infection. J Infect Dis 167: 1481–1497.
8. Flynn JL, Goldstein MM, Chobe J, Triebold KJ, Pfeffer K, et al. (1995) Tumor necrosis factor alpha is required in the protective immune response against Mycobacterium tuberculosis in mice. Immunity 2: 361–372.
9. Flynn JL, Chao J, Triebold KJ, Dalton DK, Stewart TA, et al. (1993) An essential role for interferon gamma in resistance to Mycobacterium tuberculosis infection. J Exp Med 178: 2249–2254.
10. Pearl JE, Saunders B, Ehlers S, Orme IM, Cooper AM (2001) Inflammation and lymphocyte activation during mycobacterial infection in the interferon-gamma-deficient mouse. Cell Immunol 213: 43–50.
11. Hansch HC, Smith DA, Mielke ME, Hahn H, Bancroft GJ, et al. (1996) A consensus statement. Eur Respir J 36: 1185–1206.
12. Hansch HC, Smith DA, Mielke ME, Hahn H, Bancroft GJ, et al. (1996) Class II cytokine receptors and their ligands: key antiviral and inflammatory modulators. Nat Rev Immunol 3: 667–678.
13. Ehlers S, Benini J, Held HD, Arendse B, Brown N, Myburgh E, et al. (2001) Alphabeta T cell dysfunction in mycobacterial infection after vaccination with bacille Calmette-Guerin infection. J Immunol 178: 1299–1310.
14. Cooper AM, Flynn JL (1995) The protective immune response to Mycobacterium tuberculosis. Curr Opin Immunol 7: 512–516.
15. Ehlers S, Benini J, Held HD, Rocek C, Alber G, et al. (2001) Alphabeta T cell receptor-positive cells and interferon-gamma, but not inducible nitric oxide synthase, are critical for granuloma necrosis in a mouse model of mycobacterium-induced pulmonary immunopathology. J Exp Med 194: 1847–1859.
16. Davis JM, Ramakrishnan L (2009) The role of the granuloma in expansion and degranulation of early tuberculous infection. Cell 136: 37–49.
17. Volkmann HE, Pozos TC, Zheng J, Davis JM, Rawls JF, et al. (2010) Tuberculous granuloma induction via interaction of a bacterial secreted protein with host epithelium. Science 327: 466–469.
18. Ehlers S (2010) TB or not TB? Fishing for Molecules Making Permissive granuloma in the lung. J Immunol 184: 4414–4422.
19. Zhou J, Paul WE (2000) CD4 T cells: fates, functions, and faults. Blood 96: 649–655.
20. Li W, Danilenko DM, Valdez P, Kasman I, Eastham-Anderson J, et al. (2007) Interleukin-22-2, a T(H)17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis. Nature 445: 648–651.
21. Koltzko SV, Indovina VS, Mirochnitchenko OV, Esterova E, Dickensheets H, et al. (2001) Identification of the functional interleukin-22-(IL-22) receptor complex: the IL-22Ralpha1 (IL-10Rbeta), a novel cytokine receptor component of CD4+ T cell. Int Immunol 8: 369–377.
22. Ouyang W, Rutz S, Crellin NK, Hymowitz SG (2008) IL-22: a novel T- and NK-cell derived cytokine that regulates the biology of tissue cells. Cytokine Growth Factor Rev 19: 367–380.
23. Hatzis H, Karaozsa T, Hiranuma N, Kaneko Y, Horioura K, et al. (2005) Expression of interleukin-22 in rheumatoid arthritis: potential role as a proinflammatory cytokine. Arthritis Rheum 52: 1037–1046.
24. Zheng Y, Danilenko DM, Valdez P, Kasman I, Eastham-Anderson J, et al. (2007) Interleukin-22-2, a T(H)17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis. Nature 445: 648–651.
25. Koltzko SV, Indovina VS, Mirochnitchenko OV, Esterova E, Dickensheets H, et al. (2001) Identification of the functional interleukin-22-(IL-22) receptor complex: the IL-22Ralpha1 (IL-10Rbeta), a novel cytokine receptor component of CD4+ T cell. Int Immunol 8: 369–377.
46. Mohan AK, Cote TR, Block JA, Manandan AM, Siegel JN, et al. (2004) Tuberculosis following the use of etanercept, a tumor necrosis factor inhibitor. Clin Infect Dis 39: 295–299.

47. Dhiman R, Periassamy S, Barnes PF, Jaiswal AG, Paidipally P, et al. (2012) NK1.1+ Cells and IL-22 Regulate Vaccine-Induced Protective Immunity against Challenge with Mycobacterium tuberculosis. J Immunol 189: 897–905.

48. Dhiman R, Indramohan M, Barnes PF, Nayak RC, Paidipally P, et al. (2009) IL-22 produced by human NK cells inhibits growth of Mycobacterium tuberculosis by enhancing phagolysosomal fusion. J Immunol 183: 6639–6645.

49. Wilson MS, Feng CG, Barber DL, Yarovinsky F, Cheever AW, et al. (2010) Redundant and pathogenic roles for IL-22 in mycobacterial, protozoan, and helminth infections. J Immunol 184: 4370–4380.

50. Tsai MC, Chakravarty S, Zhu G, Xu J, Tanaka K, et al. (2006) Characterization of the tuberculous granuloma in murine and human lungs: cellular composition and relative tissue oxygen tension. Cell Microbiol 8: 218–232.

51. Wang SA, Han S, Yang W, Yu H, Xu J, et al. (2011) IL-22 mediates early host defense against attaching and effacing bacterial pathogens. Nat Med 14: 282–289.

52. Dong J, Wang H, Zhang Y, Deng W, Guo Q, et al. (2008) Interleukin-22 mediates early host defense against attaching and effacing bacterial pathogens. Nat Med 14: 282–289.

53. Aujla SJ, Chan YR, Zheng M, Frei M, Askew DJ, et al. (2009) IL-22 mediates mucosal host defense against Gram-negative bacterial pneumonia. Nat Med 14: 275–281.

54. Stumhofer JS, Silver J, Hunter CA (2007) Negative regulation of Th17 responses. Semin Immunol 19: 394–399.

55. Flynn JL, Chan J (2001) Immunology of tuberculosis. Annu Rev Immunol 19: 93–129.

56. Mohan K, Cordeiro E, Vaci M, McMaster C, Issekutz TB (2005) CXCR3 is required for migration to dermal inflammation by normal and in vivo activated T cells: differential requirements by CD4 and CD8 memory subsets. Eur J Immunol 35: 1702–1711.

57. Benson HL, Mobashery S, Chang M, Kheradmand F, Houq JS, et al. (2011) Endogenous matrix metalloproteinases 2 and 9 regulate activation of CD4+ and CD8+ T cells. Am J Respir Cell Mol Biol 44: 700–708.

58. Kumar P, Thakar MS, Ouyang W, Malarkannan S (2013) IL-22 from conventional NK cells is epithelial regenerative and inflammation protective during influenza infection. Mucosal Immunol 6: 69–82.